NASDAQ:PODD - Insulet Stock Price, Price Target & More

$84.66 -0.24 (-0.28 %)

(As of 04/25/2018 02:18 PM ET)

Previous Close$84.90

Today's Range$83.87 - $85.80

52-Week Range$38.43 - $89.63

Volume106,288 shs

Average Volume476,814 shs

Market Capitalization$5.07 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.38

About Insulet (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:PODD

CUSIP45784P10

Webwww.insulet.com

Phone978-600-7000

Debt

Debt-to-Equity Ratio3.57%

Current Ratio6.24%

Quick Ratio5.85%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$463.77 million

Price / Sales10.71

Cash FlowN/A

Price / CashN/A

Book Value$2.72 per share

Price / Book31.13

Profitability

EPS (Most Recent Fiscal Year)($0.46)

Net Income$-26,830,000.00

Net Margins-5.79%

Return on Equity-29.73%

Return on Assets-4.83%

Miscellaneous

Employees857

Outstanding Shares58,690,000

How to Become a New Pot Stock Millionaire

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Wednesday, February, 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.04. The medical instruments supplier earned $130.50 million during the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. Insulet's revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Insulet.

What price target have analysts set for PODD?

20 brokerages have issued 12-month price objectives for Insulet's shares. Their forecasts range from $44.00 to $105.00. On average, they anticipate Insulet's share price to reach $76.7778 in the next twelve months. View Analyst Ratings for Insulet.

What are Wall Street analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:

1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (3/13/2018)
2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)

Who are some of Insulet's key competitors?

Some companies that are related to Insulet include ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR) and Irhythm Technologies (IRTC).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:

Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
Ms. Shacey Petrovic, Pres and Chief Operating Officer (Age 44)
Mr. Michael L. Levitz, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
Mr. Bradley A. Thomas, Exec. VP of HR & Organizational Devel. (Age 60)
Mr. Charles Alpuche, Exec. VP of Global Manufacturing and Operations (Age 58)

Has Insulet been receiving favorable news coverage?

Media headlines about PODD stock have been trending positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet earned a media sentiment score of 0.44 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 47.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $84.66.

How big of a company is Insulet?

Insulet has a market capitalization of $5.07 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]

MarketBeat Community Rating for Insulet (PODD)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		442 (Vote Outperform)
Underperform Votes:		380 (Vote Underperform)
Total Votes:		822

MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Insulet (NASDAQ:PODD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for Insulet in the last 12 months. Their average twelve-month price target is $76.7778, suggesting that the stock has a possible downside of 9.31%. The high price target for PODD is $105.00 and the low price target for PODD is $44.00. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.70	2.67	2.71	2.60
Ratings Breakdown:	0 Sell Rating(s) 6 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$76.7778	$73.5625	$62.1429	$55.4615
Price Target Upside:	9.31% downside	2.98% downside	9.62% downside	8.97% downside

Insulet (NASDAQ:PODD) Consensus Price Target History

Price Target History for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2018	Berenberg Bank	Initiated Coverage	Buy	$100.00	Medium
4/3/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Low
3/5/2018	BMO Capital Markets	Initiated Coverage	Outperform	$90.00	High
2/23/2018	Jefferies Group	Reiterated Rating	Buy	$90.00	Low
2/23/2018	Canaccord Genuity	Boost Price Target	Neutral	$78.00 -> $88.00	Low
2/22/2018	Cowen	Reiterated Rating	Outperform -> Outperform	$80.00 -> $90.00	Medium
2/22/2018	Oppenheimer	Set Price Target	Hold	$82.00	High
2/22/2018	Morgan Stanley	Reiterated Rating	Equal Weight -> Equal Weight	$76.00 -> $87.00	High
2/22/2018	Stephens	Reiterated Rating	Equal Weight -> Equal Weight	$60.00 -> $81.00	High
2/22/2018	Barclays	Reiterated Rating	Overweight -> Overweight	$85.00 -> $90.00	High
1/8/2018	Raymond James	Upgrade	Market Perform -> Outperform	$80.00	High
1/8/2018	UBS	Upgrade	Market Perform -> Outperform		High
11/3/2017	Robert W. Baird	Boost Price Target	Outperform	$65.00 -> $72.00	N/A
10/12/2017	Leerink Swann	Reiterated Rating	Outperform	$65.00 -> $74.00	N/A
10/10/2017	Wedbush	Reiterated Rating	Buy	$60.00 -> $65.00	N/A
8/4/2017	Northland Securities	Reiterated Rating	Buy		Low
7/17/2017	BTIG Research	Downgrade	Buy -> Neutral		Medium
5/25/2017	William Blair	Reiterated Rating	Outperform -> Outperform		Low
5/22/2017	Piper Jaffray	Reiterated Rating	Overweight -> Overweight	$47.00	Low
5/14/2017	B. Riley	Reiterated Rating	Neutral	$44.00	Low
2/27/2017	Feltl & Co.	Downgrade	Buy -> Hold		N/A
11/17/2016	JPMorgan Chase	Reiterated Rating	Hold	$38.00	N/A
5/16/2016	Sterne Agee CRT	Reiterated Rating	Neutral		N/A

(Data available from 4/25/2016 forward)

Insulet (NASDAQ:PODD) Earnings History and Estimates Chart

Earnings by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.23)
2019 EPS Consensus Estimate: $0.30

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	($0.22)	($0.04)	($0.14)
Q2 2018	5	($0.18)	$0.00	($0.10)
Q3 2018	6	($0.10)	$0.08	$0.03
Q4 2018	6	($0.09)	$0.08	($0.01)
Q1 2019	2	($0.04)	$0.07	$0.02
Q2 2019	2	$0.05	$0.11	$0.08
Q3 2019	2	$0.05	$0.19	$0.12
Q4 2019	2	$0.08	$0.09	$0.09

Insulet (NASDAQ PODD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		($0.19)					N/A
2/21/2018	Q4 2017	($0.08)	($0.12)	$125.16 million	$130.50 million	View	Listen
11/2/2017	Q3 2017	($0.10)	($0.04)	$114.02 million	$121.80 million	View	N/A
8/3/2017	Q2 2017	($0.13)	($0.13)	$106.23 million	$110.00 million	View	Listen
5/8/2017	Q1 2017	($0.16)	($0.17)	$97.73 million	$101.70 million	View	Listen
2/27/2017	Q416	($0.05)	($0.16)	$100.61 million	$103.58 million	View	Listen
11/3/2016	Q316	($0.09)	($0.05)	$89.75 million	$94.90 million	View	N/A
8/3/2016	Q216	($0.17)	($0.08)	$81.10 million	$87.30 million	View	N/A
4/28/2016	Q116	($0.19)	($0.19)	$79.06 million	$81.21 million	View	Listen
2/25/2016	Q415	($0.26)	($0.48)	$91.89 million	$100.10 million	View	Listen
11/5/2015	Q315	($0.26)	($0.33)	$83.56 million	$87.30 million	View	Listen
8/12/2015	Q215	($0.13)	($0.27)	$70.32 million	$75.60 million	View	Listen
4/30/2015	Q115	($0.10)	($0.21)	$68.20 million	$61.20 million	View	N/A
2/26/2015	Q414	($0.04)	($0.10)	$73.52 million	$72.60 million	View	N/A
8/7/2014	Q214	($0.08)	($0.06)	$72.94 million	$72.00 million	View	N/A
5/7/2014	Q114	($0.06)	($0.11)	$68.47 million	$69.20 million	View	N/A
2/27/2014	Q413	($0.09)	($0.04)	$67.94 million	$68.53 million	View	N/A
11/7/2013	Q313	($0.16)	($0.39)	$62.01 million	$61.10 million	View	N/A
8/7/2013	Q2 2013	($0.19)	($0.20)	$60.47 million	$60.09 million	View	N/A
5/6/2013	Q1 2013	($0.21)	($0.20)	$57.26 million	$57.40 million	View	N/A
2/27/2013	Q4 2012	($0.21)	($0.21)	$59.12 million	$57.80 million	View	N/A
11/8/2012	Q312	($0.22)	($0.26)	$54.93 million	$54.80 million	View	N/A
8/8/2012		($0.25)	($0.30)			View	N/A
5/9/2012		($0.28)	($0.31)			View	N/A
2/9/2012		($0.26)	($0.30)			View	N/A
11/3/2011		($0.25)	($0.29)			View	N/A
8/2/2011		($0.21)	($0.42)			View	N/A
5/9/2011		($0.22)	($0.22)			View	N/A
2/15/2011		($0.26)	($0.50)			View	N/A
11/9/2010	Q3 2010	($0.30)	($0.30)			View	N/A
7/29/2010	Q2 2010	($0.35)	($0.36)			View	N/A
5/6/2010	Q1 2010	($0.38)	($0.37)			View	N/A
2/9/2010	Q4 2009	($0.50)	($0.43)			View	N/A
10/26/2009	Q3 2009	($0.70)	($0.88)			View	N/A
8/4/2009	Q2 2009	($0.67)	($0.73)			View	N/A
5/7/2009	Q1 2009	($0.65)	($0.71)			View	N/A
3/5/2009	Q4 2008	($0.63)	($0.72)			View	N/A
11/6/2008	Q3 2008	($0.74)	($0.75)			View	N/A
8/12/2008	Q2 2008	($0.71)	($0.87)			View	N/A
5/13/2008	Q1 2008	($0.52)	($0.73)			View	N/A
3/17/2008	Q4 2007	($0.50)	($0.59)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Insulet (NASDAQ:PODD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.60%

Insider Trading History for Insulet (NASDAQ:PODD)

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ PODD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2018	Bradley A. Thomas	EVP	Sell	3,500	$85.00	$297,500.00
3/15/2018	Charles Alpuche	COO	Sell	7,090	$84.65	$600,168.50
3/14/2018	Bradley A. Thomas	EVP	Sell	7,250	$83.81	$607,622.50
3/14/2018	John A. Fallon	Director	Sell	9,000	$84.10	$756,900.00
3/6/2018	David A. Lemoine	Director	Sell	641	$76.81	$49,235.21
3/6/2018	Shacey Petrovic	COO	Sell	1,319	$76.81	$101,312.39
11/13/2017	James C. Mullen	Director	Buy	2,500	$67.45	$168,625.00
9/6/2017	Charles Alpuche	EVP	Buy	2,500	$58.08	$145,200.00
5/16/2017	Michael P. Spears	SVP	Buy	2,500	$40.59	$101,475.00
5/11/2017	Bradley A. Thomas	EVP	Buy	3,000	$38.69	$116,070.00
5/11/2017	Jessica Hopfield	Director	Buy	2,580	$38.68	$99,794.40
5/1/2017	David A. Lemoine	Director	Sell	1,524	$43.40	$66,141.60
3/13/2017	Regina O. Sommer	Director	Sell	40,000	$45.00	$1,800,000.00
3/6/2017	David A. Lemoine	Director	Sell	1,282	$45.15	$57,882.30
3/2/2017	Joseph S. Zakrzewski	Director	Sell	40,000	$46.86	$1,874,400.00
12/9/2016	Charles Alpuche	SVP	Buy	6,600	$37.70	$248,820.00
12/2/2016	Patrick J. Sullivan	CEO	Buy	40,000	$33.89	$1,355,600.00
12/1/2016	Bradley A. Thomas	EVP	Buy	3,100	$32.45	$100,595.00
5/25/2016	Regina O Sommer	Director	Sell	8,019	$30.42	$243,937.98	20,330
5/18/2016	Patrick J Sullivan	CEO	Buy	45,000	$27.00	$1,215,000.00	202,795
5/13/2016	Bradley A Thomas	EVP	Buy	2,975	$26.63	$79,224.25	51,315
5/5/2016	Bradley A Thomas	EVP	Buy	1,656	$30.13	$49,895.28	48,340
3/10/2016	Daniel J Levangie	Insider	Sell	12,299	$30.89	$379,916.11	25,358
3/7/2016	Daniel J Levangie	Insider	Sell	7,663	$31.15	$238,702.45	9,813
3/2/2016	Jessica Hopfield	Director	Buy	3,230	$30.91	$99,839.30	8,838
6/5/2015	Patrick J Sullivan	CEO	Buy	10,000	$29.39	$293,900.00
5/28/2015	Patrick J Sullivan	CEO	Buy	20,000	$27.91	$558,200.00
5/15/2015	Timothy J Scannell	Director	Buy	3,500	$27.05	$94,675.00
5/5/2015	Bradley A Thomas	EVP	Buy	1,000	$27.26	$27,260.00
5/5/2015	Patrick Ryan	COO	Buy	3,669	$26.99	$99,026.31
4/2/2015	R Anthony Diehl	General Counsel	Sell	3,372	$30.96	$104,397.12
3/9/2015	Patrick J Sullivan	CEO	Buy	10,000	$31.93	$319,300.00
3/2/2015	Charles T Liamos	Director	Sell	4,000	$32.00	$128,000.00
2/12/2015	Charles T Liamos	Director	Sell	4,000	$32.00	$128,000.00
1/2/2015	Charles T Liamos	Director	Sell	4,000	$46.08	$184,320.00
11/3/2014	Charles T Liamos	Director	Sell	4,000	$42.95	$171,800.00
10/1/2014	Charles T Liamos	Director	Sell	4,000	$36.58	$146,320.00
10/1/2014	R Anthony Diehl	General Counsel	Sell	1,250	$36.59	$45,737.50
9/10/2014	Charles T Liamos	Director	Sell	4,000	$35.17	$140,680.00
9/2/2014	Duane Desisto	CEO	Sell	20,000	$36.30	$726,000.00
8/1/2014	Duane Desisto	CEO	Sell	20,000	$34.23	$684,600.00
7/1/2014	Duane Desisto	CEO	Sell	20,000	$40.52	$810,400.00
7/1/2014	R Anthony Diehl	General Counsel	Sell	1,250	$39.65	$49,562.50
6/11/2014	R Anthony Diehl	General Counsel	Sell	17,871	$37.09	$662,835.39
6/9/2014	Peter Devlin	Insider	Sell	12,314	$37.10	$456,849.40
4/8/2014	Peter Devlin	Insider	Sell	30,000	$41.25	$1,237,500.00	79,668
4/3/2014	R Anthony Diehl	General Counsel	Sell	4,617	$48.67	$224,709.39	53,246
3/6/2014	R Anthony Diehl	General Counsel	Sell	12,458	$49.28	$613,930.24	58,246
3/6/2014	Tracey Haas Wielinski	VP	Sell	8,275	$49.21	$407,212.75	24,000
2/3/2014	Charles Liamos	Director	Sell	11,037	$42.93	$473,818.41	77,316
2/3/2014	Duane Desisto	CEO	Sell	20,000	$42.95	$859,000.00	184,293
2/3/2014	Peter Devlin	Insider	Sell	30,000	$42.82	$1,284,600.00	63,081
1/3/2014	Charles Liamos	COO	Sell	86,000	$36.02	$3,097,720.00	77,316
1/2/2014	Duane Desisto	CEO	Sell	20,000	$36.07	$721,400.00	184,293
12/3/2013	Charles Liamos	COO	Sell	63,808	$36.26	$2,313,678.08	118,194
11/18/2013	Charles Liamos	COO	Sell	80,000	$35.60	$2,848,000.00	118,194
9/3/2013	Duane Desisto	CEO	Sell	20,000	$33.38	$667,600.00	182,433
8/29/2013	Sally Crawford	Director	Sell	9,000	$33.42	$300,780.00	7,000
8/15/2013	Regina Sommer	Director	Sell	5,000	$33.32	$166,600.00	16,500
8/1/2013	Duane Desisto	CEO	Sell	20,000	$31.85	$637,000.00
7/1/2013	Duane Desisto	CEO	Sell	20,000	$31.51	$630,200.00
7/1/2013	Peter Devlin	Insider	Sell	30,000	$31.48	$944,400.00
6/14/2013	Sally Crawford	Director	Sell	31,000	$30.47	$944,570.00
6/10/2013	R Anthony Diehl	General Counsel	Sell	38,455	$30.50	$1,172,877.50
6/3/2013	Duane Desisto	CEO	Sell	20,000	$29.76	$595,200.00
12/3/2012	Brian K Roberts	CFO	Sell	10,000	$21.92	$219,200.00
11/1/2012	Brian K Roberts	CFO	Sell	10,000	$21.49	$214,900.00
9/4/2012	Brian K Roberts	CFO	Sell	10,000	$20.78	$207,800.00
9/4/2012	Duane Desisto	CEO	Sell	20,000	$20.97	$419,400.00
9/4/2012	Ruthann Depietro	VP	Sell	1,000	$20.90	$20,900.00

(Data available from 1/1/2013 forward)

Insulet (NASDAQ PODD) News Headlines

Source:

Date	Headline
	Global Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas Corporation www.marketwatch.com - April 24 at 9:03 AM
	Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million www.americanbankingnews.com - April 23 at 5:32 AM
	Zacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per Share www.americanbankingnews.com - April 21 at 1:20 AM
	Insulet (PODD) Earns Buy Rating from Analysts at Berenberg Bank www.americanbankingnews.com - April 20 at 9:22 AM
	Insulet (PODD) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 17 at 8:07 PM
	Insulet (PODD) Downgraded by BidaskClub to "Buy" www.americanbankingnews.com - April 14 at 4:46 PM
	Edited Transcript of PODD presentation 7-Mar-17 4:35pm GMT finance.yahoo.com - April 12 at 9:53 AM
	Insulet (PODD) Given "Buy" Rating at Wedbush www.americanbankingnews.com - April 7 at 6:04 PM
	BRIEF-Insulet Corp Says CEO's 2017 Total Compensation Was $8.2 Mln Vs $6 Mln In 2016 www.reuters.com - April 6 at 4:59 PM
	Insulet Co. (PODD) Expected to Announce Quarterly Sales of $121.60 Million www.americanbankingnews.com - April 6 at 4:43 AM
	Insulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - April 4 at 9:34 PM
	Analysts Anticipate Insulet Co. (PODD) Will Post Earnings of -$0.19 Per Share www.americanbankingnews.com - April 4 at 3:06 AM
	Insulet (PODD) Coverage Initiated at Guggenheim www.americanbankingnews.com - April 3 at 5:16 PM
	Insulet (PODD) Upgraded by ValuEngine to "Buy" www.americanbankingnews.com - April 3 at 10:32 AM
	Global Insulin delivery system Market Opportunities 2018: Insulet Corporation, Ypsomed Holding AG, Becton www.marketwatch.com - April 3 at 9:20 AM
	Zacks Investment Research Upgrades Insulet (PODD) to Hold www.americanbankingnews.com - March 25 at 10:56 PM
	BidaskClub Upgrades Insulet (PODD) to Strong-Buy www.americanbankingnews.com - March 23 at 7:56 PM
	Insider Selling: Insulet Co. (PODD) EVP Sells 3,500 Shares of Stock www.americanbankingnews.com - March 20 at 7:50 PM
	Insulet (PODD) Upgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 18 at 11:18 AM
	Insider Selling: Insulet Co. (PODD) COO Sells 7,090 Shares of Stock www.americanbankingnews.com - March 16 at 7:35 PM
	Insider Selling: Insulet Co. (PODD) EVP Sells 7,250 Shares of Stock www.americanbankingnews.com - March 16 at 7:33 PM
	John A. Fallon Sells 9,000 Shares of Insulet Co. (PODD) Stock www.americanbankingnews.com - March 16 at 7:33 PM
	Insulet Co. (PODD) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - March 10 at 9:40 PM
	Insulet (PODD) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - March 10 at 4:58 PM
	David A. Lemoine Sells 641 Shares of Insulet Co. (PODD) Stock www.americanbankingnews.com - March 8 at 9:50 PM
	Insulet Co. (PODD) COO Sells $101,312.39 in Stock www.americanbankingnews.com - March 8 at 9:35 PM
	Analyst: Insulet On Track For Profitability In 2018 finance.yahoo.com - March 6 at 5:04 PM
	240,327 Shares in Insulet Co. (PODD) Purchased by OppenheimerFunds Inc. www.americanbankingnews.com - March 6 at 11:36 AM
	Insulet Co. (PODD) Position Increased by Arrowstreet Capital Limited Partnership www.americanbankingnews.com - March 6 at 4:38 AM
	Insulet (PODD) Coverage Initiated at BMO Capital Markets www.americanbankingnews.com - March 5 at 8:24 PM
	Sectoral Asset Management Inc Invests $6.52 Million in Insulet Co. (PODD) Stock www.americanbankingnews.com - March 5 at 4:07 PM
	54,207 Shares in Insulet Co. (PODD) Purchased by Lombard Odier Asset Management USA Corp www.americanbankingnews.com - March 3 at 4:42 PM
	Insulet Co. (PODD) Stake Lowered by Next Century Growth Investors LLC www.americanbankingnews.com - March 3 at 3:53 PM
	Zacks: Analysts Expect Insulet Co. (PODD) Will Post Quarterly Sales of $121.60 Million www.americanbankingnews.com - March 2 at 1:50 AM
	-$0.19 EPS Expected for Insulet Co. (PODD) This Quarter www.americanbankingnews.com - February 28 at 11:11 PM
	Teacher Retirement System of Texas Has $1.37 Million Holdings in Insulet Co. (PODD) www.americanbankingnews.com - February 28 at 5:07 PM
	Insulet Corporation to Present at Upcoming Investor Conferences finance.yahoo.com - February 28 at 9:02 AM
	Insulet Co. (PODD) Holdings Reduced by Champlain Investment Partners LLC www.americanbankingnews.com - February 27 at 5:38 AM
	Q3 2018 Earnings Estimate for Insulet Co. Issued By Northcoast Research (PODD) www.americanbankingnews.com - February 26 at 4:48 AM
	Oppenheimer Weighs in on Insulet Co.'s Q3 2018 Earnings (PODD) www.americanbankingnews.com - February 26 at 4:38 AM
	Q1 2018 EPS Estimates for Insulet Co. Lowered by Analyst (PODD) www.americanbankingnews.com - February 26 at 2:06 AM
	William Blair Brokers Reduce Earnings Estimates for Insulet Co. (PODD) www.americanbankingnews.com - February 26 at 2:06 AM
	Research Analysts Set Expectations for Insulet Co.'s Q1 2018 Earnings (PODD) www.americanbankingnews.com - February 26 at 2:06 AM
	Swiss National Bank Has $6.82 Million Position in Insulet Co. (PODD) www.americanbankingnews.com - February 25 at 6:38 AM
	Insulet's (PODD) "Buy" Rating Reiterated at Jefferies Group www.americanbankingnews.com - February 24 at 3:48 PM
	Insulet (PODD) PT Raised to $88.00 at Canaccord Genuity www.americanbankingnews.com - February 23 at 9:44 PM
	8 Stocks Getting Multiple Analyst Upgrades and Downgrades After Earnings and News www.msn.com - February 23 at 5:14 PM
	Equities Analysts Offer Predictions for Insulet Co.'s Q4 2019 Earnings (PODD) www.americanbankingnews.com - February 23 at 4:34 PM
	Insulet Co. (PODD) Expected to Post Q1 2019 Earnings of ($0.04) Per Share www.americanbankingnews.com - February 23 at 2:36 PM
	Research Analysts Set Expectations for Insulet Co.'s Q3 2018 Earnings (PODD) www.americanbankingnews.com - February 23 at 11:54 AM

Insulet (NASDAQ:PODD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement

Insulet (NASDAQ PODD) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff